Timber Pharmaceuticals Inc. (AMEX: TMBR) stock fell -3.97% on Friday to $0.22 against a previous-day closing price of $0.23. With 1.06 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.92 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.2300 whereas the lowest price it dropped to was $0.2143. The 52-week range on TMBR shows that it touched its highest point at $1.12 and its lowest point at $0.22 during that stretch. It currently has a 1-year price target of $1.50. Beta for the stock currently stands at 0.28.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TMBR was down-trending over the past week, with a drop of -19.95%, but this was down by -27.12% over a month. Three-month performance dropped to -18.54% while six-month performance fell -28.32%. The stock lost -77.22% in the past year, while it has lost -42.66% so far this year.
Float and Shares Shorts:
At present, 64.07 million TMBR shares are outstanding with a float of 63.59 million shares on hand for trading. On Apr 28, 2022, short shares totaled 0.54 million, which was 0.85% higher than short shares on Mar 30, 2022. In addition to Mr. John Koconis M.B.A. as the firm’s Chairman, CEO & Pres, Mr. Joseph Lucchese serves as its Exec. VP, CFO, Treasurer & Sec.
Institutional Ownership:
Through their ownership of 4.65% of TMBR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 2.18% of TMBR, in contrast to 2.08% held by mutual funds. Shares owned by individuals account for 15.91%. As the largest shareholder in TMBR with 1.81% of the stake, The Vanguard Group, Inc. holds 1,154,694 shares worth 1,154,694. A second-largest stockholder of TMBR, Renaissance Technologies LLC, holds 871,237 shares, controlling over 1.37% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in TMBR, holding 205,720 shares or 0.32% stake. With a 1.42% stake in TMBR, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 902,107 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.40% of TMBR stock, is the second-largest Mutual Fund holder. It holds 252,587 shares valued at 79565.0. Fidelity Extended Market Index Fu holds 0.26% of the stake in TMBR, owning 163,593 shares worth 51532.0.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TMBR since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With TMBR analysts setting a high price target of $1.50 and a low target of $1.50, the average target price over the next 12 months is $1.50. Based on these targets, TMBR could surge 581.82% to reach the target high and rise by 581.82% to reach the target low. Reaching the average price target will result in a growth of 581.82% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. TMBR will report FY 2022 earnings on 03/21/2023. Analysts have provided yearly estimates in a range of -$0.19 being high and -$0.19 being low. For TMBR, this leads to a yearly average estimate of -$0.19. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Timber Pharmaceuticals Inc. surprised analysts by -$0.01 when it reported -$0.05 EPS against a consensus estimate of -$0.04. The surprise factor in the prior quarter was $0.02. Based on analyst estimates, the high estimate for the next quarter is -$0.04 and the low estimate is -$0.04. The average estimate for the next quarter is thus -$0.04.
Summary of Insider Activity:
Insiders traded TMBR stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 8 while that of sell transactions has risen to 8 over the past year. The total number of shares bought during that period was 574,326 while 719,630 shares were sold.
